Scientific Reports (Jul 2017)

Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1

  • Fu-Chao Liu,
  • Huang-Ping Yu,
  • Yu-Ting Syu,
  • Jia-You Fang,
  • Chwan-Fwu Lin,
  • Shih-Hsin Chang,
  • Yen-Tung Lee,
  • Tsong-Long Hwang

DOI
https://doi.org/10.1038/s41598-017-07131-w
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Formyl peptide receptor 1 (FPR1) mediates bacterial and mitochondrial N-formyl peptides-induced neutrophil activation. Therefore, FPR1 is an important therapeutic target for drugs to treat septic or sterile inflammatory diseases. Honokiol, a major bioactive compound of Magnoliaceae plants, possesses several anti-inflammatory activities. Here, we show that honokiol exhibits an inhibitory effect on FPR1 binding in human neutrophils. Honokiol inhibited superoxide anion generation, reactive oxygen species formation, and elastase release in bacterial or mitochondrial N-formyl peptides (FPR1 agonists)-activated human neutrophils. Adhesion of FPR1-induced human neutrophils to cerebral endothelial cells was also reduced by honokiol. The receptor-binding results revealed that honokiol repressed FPR1-specific ligand N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-fluorescein binding to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells. However, honokiol did not inhibit FPR2-specific ligand binding to FPR2 in human neutrophils. Furthermore, honokiol inhibited FPR1 agonist-induced calcium mobilization as well as phosphorylation of p38 MAPK, ERK, and JNK in human neutrophils. In conclusion, our data demonstrate that honokiol may have therapeutic potential for treating FPR1-mediated inflammatory diseases.